194 related articles for article (PubMed ID: 29496349)
21. An economic case for a vaccine to prevent group A streptococcus skin infections.
Cannon JW; Jack S; Wu Y; Zhang J; Baker MG; Geelhoed E; Fraser J; Carapetis JR
Vaccine; 2018 Nov; 36(46):6968-6978. PubMed ID: 30340879
[TBL] [Abstract][Full Text] [Related]
22. Status of research and development of vaccines for Streptococcus pyogenes.
Steer AC; Carapetis JR; Dale JB; Fraser JD; Good MF; Guilherme L; Moreland NJ; Mulholland EK; Schodel F; Smeesters PR
Vaccine; 2016 Jun; 34(26):2953-2958. PubMed ID: 27032515
[TBL] [Abstract][Full Text] [Related]
23. Systematic Review and Meta-analysis of the Prevalence of Group A Streptococcal
Salie T; Engel K; Moloi A; Muhamed B; Dale JB; Engel ME
mSphere; 2020 Jul; 5(4):. PubMed ID: 32669471
[TBL] [Abstract][Full Text] [Related]
24. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004.
O'Loughlin RE; Roberson A; Cieslak PR; Lynfield R; Gershman K; Craig A; Albanese BA; Farley MM; Barrett NL; Spina NL; Beall B; Harrison LH; Reingold A; Van Beneden C;
Clin Infect Dis; 2007 Oct; 45(7):853-62. PubMed ID: 17806049
[TBL] [Abstract][Full Text] [Related]
25. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.
Tsoi SK; Smeesters PR; Frost HR; Licciardi P; Steer AC
J Immunol Res; 2015; 2015():167089. PubMed ID: 26101780
[TBL] [Abstract][Full Text] [Related]
26. The quest for GAS vaccine.
Pandey M; Good MF
Oncotarget; 2015 Oct; 6(33):34063-4. PubMed ID: 26485764
[No Abstract] [Full Text] [Related]
27. The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations.
Vekemans J; Crofts J; Baker CJ; Goldblatt D; Heath PT; Madhi SA; Le Doare K; Andrews N; Pollard AJ; Saha SK; Schrag SJ; Smith PG; Kaslow DC
Vaccine; 2019 May; 37(24):3190-3198. PubMed ID: 31031031
[TBL] [Abstract][Full Text] [Related]
28. Disease manifestations and pathogenic mechanisms of Group A Streptococcus.
Walker MJ; Barnett TC; McArthur JD; Cole JN; Gillen CM; Henningham A; Sriprakash KS; Sanderson-Smith ML; Nizet V
Clin Microbiol Rev; 2014 Apr; 27(2):264-301. PubMed ID: 24696436
[TBL] [Abstract][Full Text] [Related]
29. Molecular Epidemiology of Noninvasive and Invasive Group A Streptococcal Infections in Cape Town.
Barth DD; Naicker P; Engel K; Muhamed B; Basera W; Mayosi BM; Dale JB; Engel ME
mSphere; 2019 Oct; 4(5):. PubMed ID: 31666314
[TBL] [Abstract][Full Text] [Related]
30. Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study.
Osowicki J; Azzopardi KI; Baker C; Waddington CS; Pandey M; Schuster T; Grobler A; Cheng AC; Pollard AJ; McCarthy JS; Good MF; Walker MJ; Dale JB; Batzloff MR; Carapetis JR; Smeesters PR; Steer AC
Vaccine; 2019 Jun; 37(26):3485-3494. PubMed ID: 31101422
[TBL] [Abstract][Full Text] [Related]
31. Pathogenesis of group A streptococcal infections.
Henningham A; Barnett TC; Maamary PG; Walker MJ
Discov Med; 2012 May; 13(72):329-42. PubMed ID: 22642914
[TBL] [Abstract][Full Text] [Related]
32. Group A streptococcal infections of the skin: molecular advances but limited therapeutic progress.
Currie BJ
Curr Opin Infect Dis; 2006 Apr; 19(2):132-8. PubMed ID: 16514337
[TBL] [Abstract][Full Text] [Related]
33. Group A streptococcus.
Martin JM; Green M
Semin Pediatr Infect Dis; 2006 Jul; 17(3):140-8. PubMed ID: 16934708
[TBL] [Abstract][Full Text] [Related]
34. A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes.
Bi S; Xu M; Zhou Y; Xing X; Shen A; Wang B
mBio; 2019 Nov; 10(6):. PubMed ID: 31772056
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
[TBL] [Abstract][Full Text] [Related]
36. Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine.
Zaman M; Skwarczynski M; Malcolm JM; Urbani CN; Jia Z; Batzloff MR; Good MF; Monteiro MJ; Toth I
Nanomedicine; 2011 Apr; 7(2):168-73. PubMed ID: 21034860
[TBL] [Abstract][Full Text] [Related]
37.
Wang J; Ma C; Li M; Gao X; Wu H; Dong W; Wei L
Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766186
[No Abstract] [Full Text] [Related]
38. A vaccine against Streptococcus pyogenes: the potential to prevent rheumatic fever and rheumatic heart disease.
Guilherme L; Ferreira FM; Köhler KF; Postol E; Kalil J
Am J Cardiovasc Drugs; 2013 Feb; 13(1):1-4. PubMed ID: 23355360
[TBL] [Abstract][Full Text] [Related]
39. Group A streptococcal emm type prevalence among symptomatic children in Cape Town and potential vaccine coverage.
Engel ME; Muhamed B; Whitelaw AC; Musvosvi M; Mayosi BM; Dale JB
Pediatr Infect Dis J; 2014 Feb; 33(2):208-10. PubMed ID: 23934204
[TBL] [Abstract][Full Text] [Related]
40. Update on group A streptococcal vaccine development.
Dale JB; Walker MJ
Curr Opin Infect Dis; 2020 Jun; 33(3):244-250. PubMed ID: 32304470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
